# CLNN catalysts: Clene Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/clnn/catalysts

> Clene Inc. (CLNN) has no upcoming catalysts in this calendar. The latest recorded is the Clene Inc. earnings report, November 4, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Clene Inc. |
| Ticker | CLNN (Nasdaq) |
| SEC CIK | 1822791 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/clnn |

## Cash runway

Cash $9.9M as of 2026-09-30; quarterly burn $4.6M; about 6.4 months of runway at that rate (XBRL company facts, accession 0001437749-26-034776).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Oct 2022 | [CNM-Au8 (cnm-au8) topline data readout](https://sec-api.dev/pdufa/cnm-au8) | CLNN |  | completed, mixed | "In October 2022, we announced topline results for CNM-Au8: the primary endpoint of rate of change in ALSFRS-R adjusted for mortality was not statistically significant at 24 weeks (2% slowing, 95% CI: -20% to +19%)." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1822791/000143774925008956/clnn20241231_10k.htm)) |
| November 13, 2024 | [Clene Inc. earnings report](https://sec-api.dev/companies/clnn/catalysts) | CLNN |  | completed | "CLENE REPORTS Third QUARTER 2024 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774924034668/ex_714259.htm)) |
| March 24, 2025 | [Clene Inc. earnings report](https://sec-api.dev/companies/clnn/catalysts) | CLNN |  | completed | "CLENE REPORTS FULL YEAR 2024 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774925008869/ex_727055.htm)) |
| May 6, 2025 | [Clene Inc. earnings report](https://sec-api.dev/companies/clnn/catalysts) | CLNN |  | completed | "CLENE REPORTS First QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774925014917/ex_763001.htm)) |
| 2H 2025 | [Clene Inc. topline data readout](https://sec-api.dev/companies/clnn/catalysts) | CLNN |  | scheduled | "We also concluded enrollment of Cohort 2, comprised of 15 participants with non-active progressive MS, in January 2025 with topline results expected during the second half of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1822791/000143774925008956/clnn20241231_10k.htm)) |
| August 13, 2025 | [Clene Inc. earnings report](https://sec-api.dev/companies/clnn/catalysts) | CLNN |  | completed | "CLENE REPORTS Second QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774925026690/ex_829965.htm)) |
| Q4 2025 | [CNM-Au8 (cnm-au8) NDA/BLA submission](https://sec-api.dev/pdufa/cnm-au8) | CLNN |  | scheduled | "The Company expects to submit a New Drug Application in the fourth quarter of 2025 for potential accelerated approval of CNM-Au8® in ALS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774925026690/ex_829965.htm)) |
| November 13, 2025 | [Clene Inc. earnings report](https://sec-api.dev/companies/clnn/catalysts) | CLNN |  | completed | "CLENE REPORTS Third QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774925034621/ex_855915.htm)) |
| Jan 2026 | [Clene Inc. NDA/BLA acceptance](https://sec-api.dev/companies/clnn/catalysts) | CLNN |  | completed | "Subject to FDA acceptance of the NDA for review, the Company could receive $6.7 million to $7.8 million in proceeds from common stock warrants issued in its January 2026 financing." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774926034775/ex_1007139.htm)) |
| Q1 2026 | [CNM-Au8 (cnm-au8) PDUFA date](https://sec-api.dev/pdufa/cnm-au8) | CLNN |  | scheduled | "The exercise price of each Series A Warrant will increase to $7.00 per share if either: (a) the warrant is exercised prior to the Company's public announcement of the FDA's posted PDUFA action date for the CNM-Au8 NDA (the "PDUFA Date Announcement"), which is expected to occur in the first quarter of 2026; or (b) the volume-weighted average price of the Company's common stock equals or exceeds $10.00 on the measurement date associated with the PDUFA Date Announcement." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774926001196/ex_905866.htm)) |
| March 12, 2026 | [Clene Inc. earnings report](https://sec-api.dev/companies/clnn/catalysts) | CLNN |  | completed | "CLENE REPORTS FULL YEAR 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774926007828/ex_874803.htm)) |
| May 11, 2026 | [Clene Inc. earnings report](https://sec-api.dev/companies/clnn/catalysts) | CLNN |  | completed | "CLENE REPORTS First QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774926016881/ex_908797.htm)) |
| June 16, 2026 | [CNM-Au8 (cnm-au8) NDA/BLA acceptance](https://sec-api.dev/pdufa/cnm-au8) | CLNN |  | completed | "The Tranche A Warrants were exercisable immediately and will expire on the earlier of (i) sixty (60) days following the date of our public announcement that the filing of a New Drug Application ("NDA") for CNM-Au8 has been accepted by the U.S. Food and Drug Administration ("FDA"), or (ii) June 16, 2026." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1822791/000143774926030521/clnn20260911_424b5.htm)) |
| 2H 2026 | [Clene Inc. PDUFA date](https://sec-api.dev/companies/clnn/catalysts) | CLNN |  | scheduled | "FDA acceptance of this NDA and issuance of a Prescription Drug User Fee Act (PDUFA) date for regulatory decision under the accelerated approval pathway could occur in the second half of 2026, with potential approval for commercial launch in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774926005156/ex_924033.htm)) |
| August 14, 2026 | [Clene Inc. earnings report](https://sec-api.dev/companies/clnn/catalysts) | CLNN |  | completed | "CLENE REPORTS Second QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774926027837/ex_967804.htm)) |
| Q4 2026 | [CNM-Au8 (cnm-au8) NDA/BLA submission](https://sec-api.dev/pdufa/cnm-au8) | CLNN |  | scheduled | "Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774926027837/ex_967804.htm)) |
| October 19, 2026 | [CNM-Au8 (cnm-au8) NDA/BLA submission](https://sec-api.dev/pdufa/cnm-au8) | CLNN | amyotrophic lateral sclerosis | completed | "SALT LAKE CITY, October 19, 2026 — Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on revolutionizing the treatment of neurodegenerative diseases, announced that it has submitted a New Drug Application (NDA) earlier in October to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of CNM-Au8® for the treatment of amyotrophic lateral sclerosis (ALS)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774926032882/ex_1027473.htm)) |
| November 4, 2026 | [Clene Inc. earnings report](https://sec-api.dev/companies/clnn/catalysts) | CLNN |  | completed | "CLENE REPORTS Third QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774926034775/ex_1007139.htm)) |

## Drugs

- [CNM-Au8 (cnm-au8)](https://sec-api.dev/pdufa/cnm-au8): amyotrophic lateral sclerosis

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/clnn/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CLNN catalysts: Clene Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/clnn/catalysts

```bibtex
@misc{secapidev_companies_clnn_catalysts_20261116,
  title        = {CLNN catalysts: Clene Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/clnn/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_clnn_catalysts_20261116","title":"CLNN catalysts: Clene Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/clnn/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
